Innovative Technology Company Invents Real “Star Trek” Medical Scanner That Diagnoses Patient Health in Seconds.
MAYBE you’re old enough to remember Dr. Leonard “Bones” McCoy, the surgeon aboard the U.S.S. Enterprise starship from the original “Star Trek” TV series.
During a field mission, when a crew member was ill, Dr. McCoy used a “tricorder ” – a tiny handheld medical diagnostic instrument – to read the patient’s vital signs in seconds. And he didn’t have to take a blood sample or puncture the skin with a needle to do it.
Well, now a technology company that recently went public – Biozoom, Inc. (BIZM)
www.biozoom.net – has developed a real-life tricorder: the Biozoom Biofeedback Scanner.
It’s the only handheld diagnostic device of its kind worldwide that tests for your health without blood tests or piercing your skin.
But the Biozoom Scanner, developed in partnership with Carl Zeiss and Vodafone, isn’t science fiction. It exists now, and has already been successfully tested on 1,200 patients. Units have been used by doctors in hospital settings – and will soon be available to other health care professionals and the general public.
That means you’ll be able to monitor your blood chemistry at home – in seconds – without having your blood drawn through a needle at a diagnostic lab, and then waiting 3 to 5 days for the results. Or paying a big lab bill.
Is It The Tech Stock That Will Change The Healthcare Paradigm?
Biozoom analysis takes only 16 milliseconds, and it’s completely noninvasive. A beam of light detects and measures antioxidant levels … vitamins … oxidative stress … and cyotochrom oxidase, a critical enzyme that aids in the production of energy in your cells. Planned upgrades will enable measurement of blood alcohol, cholesterol, drugs, chronic venous insufficiency, blood pressure, smoke poisoning, oxygen saturation HbO2, and even blood sugar levels – an essential daily test for diabetics that currently requires a pin-prick with a sharp needle. The cost of treating diabetes in the United States is $220 billion a year.
Why Is The Home Health Diagnostic Market So Hot?
One factor fueling the demand for home health tests is the lagging economy, which has left millions of Americans without health insurance coverage to pay for medical laboratory tests. Bloomberg reports that the do-it-yourself home health test market, estimated at $2 billion to $3 billion globally, is growing by 20% a year.
Medical devices account for 6% of U.S. health care spending. In 2010, the last year studied, spending on medical devices and in-vitro diagnostics totaled $156.3 billion. The global home healthcare device industry is expected to reach $29 billion in 2017.
Biozoom’s invention could grab significant market share in this rapidly growing segment.
Game-Changing Medical Optics
The core technology behind Biozoom is its proprietary algorithm and the game-changing optics designed by Carl Zeiss, a global leader in optical engineering. Biozoom (BIZM) has the right to use the Carl Zeiss name in its marketing, which adds instant credibility to the product.
In essence, the Biozoom Scanner is a spectrophotometer, meaning it identifies substances by the unique spectrum they reflect. The device radiates light into the skin using specially developed LEDs, and the light spectrum reflected from the skin contains spectroscopic information – which is absorbed by a photo-detector and analyzed using a proprietary Biozoom algorithm.
Subscription-Based Business Model
Biozoom’s subscriptionbased model gives it two core revenue streams. The company makes money from the sale of the handheld device, expected to retail for around $200. The second income stream is recurring monthly revenue from a subscription to the Biozoom algorithm for providing biometric read-outs and health advice based on those results.
Hold Better Health In The Palm Of Your Hand
The low-hanging fruit for Biozoom (BIZM) is in wellness applications. In a test of 50 students, 20% of the students stopped smoking after using the device – and 83% increased their levels of antioxidants after 2 months.
The versatility of the Biozoom Scanner gives it broad applicability, including 29,960 health clubs in the U.S., corporate wellness programs, and the spa industry.
There are even applications outside of health, wellness, and beauty. In the near future, both law enforcement officers and drivers will be able to use the Biozoom Scanner to measure blood alcohol levels. The Biozoom spectrometer can also be used to measure components of car and truck emissions, meaning potential partnerships within the automotive industry.
Biozoom’s Nanotechnology Future
The company’s R&D laboratory is developing its nextgeneration biomarker scanner, a chip-sized version of the Biozoom spectrometer. A major application for the miniaturized version is integration into smart phones, laptops and tablets. The nanospectrometer could even be integrated into consumer devices such as toothbrushes, electric razors, hair dryers or cosmetics cases.
The Doctor’s Friend
Physicians and other health care professionals can eliminate lab delays and costs for their patients by taking biomarker readings in their office during exams with the Biozoom Scanner. In 2012, there were 834,769 active physicians in the U.S. and 18,000 hospitals worldwide. Use of the Biozoom Scanner will provides the opportunity to scan patients, instantly have results, and apply the knowledge to health, fitness and lifestyle adjustments and goals.
Partnering For Distribution
Biozoom (BIZM) isn’t just going to sell scanners to consumers and physicians. The company has plans to actively pursue partnerships with major corporations in a position to benefit from use of the Biozoom Scanner. These include companies like Nutrilite, GNC, CVS, NuSkin, Neuform, P&G, Walmart, Walgreens, Target, Media Mart, and Rossman.
Multimillion-Dollar IP Portfolio
Biozoom (BIZM) has filed 19 patents in such areas as optics, temperature drift, database management, nanospectroscopy, fuel consumption, fitness enzymes, and others. As a result, its portfolio of intellectual property is expected to become a multimillion-dollar asset with huge income potential should the company decide to license some of its technology innovations.
The Future Of Health Care And Self-Care
Given Biozoom’s incredible advancements in nano-optics, it’s only a matter of time before analysts and the mainstream media get wind of the story. The company will not fly under the radar of Wall Street gurus for long.
It’s difficult to put a ceiling on the growth of a technology company with a game-changing technology, especially in the booming field of health care.
The company could grow to the point where Biozoom absolutely dominates the biometric device niche – or they might become a prime target for acquisition by an industry giant. Either way, Biozoom Biozoom (BIZM) (BIZM) could be one of the best tech stocks for 2013 and beyond.